Time-Cap Labs, Inc. has been acquired by Marksans Pharma Ltd.
The founder and owner of Time-Cap Labs, Inc. has sold the company to Marksans Pharma Limited for an undisclosed consideration.
Founded in 1978 and based in Farmingdale, New York, Time-Cap Labs, Inc. manufactures and supplies generic pharmaceuticals and over-the-counter drugs. The company specializes in delayed and sustained release dosages. It offers various formulations, including analgesics, laxatives, dietary supplements, cough and cold medications, prescription drugs, antacids, and other products. The company offers its products to large and small wholesalers and distributors.
Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.
One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.
Talk to the deal team
Paul R. Smolevitz
Oaklins TM Capital
James McLaren
Oaklins TM Capital
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more